Sugi Predict
/ Targets
/ BRD4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to BRD4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD |
PHASE3 | COMPLETED |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma |
PHASE1/PHASE2 | RECRUITING |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial |
PHASE2 | RECRUITING |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis |
PHASE1/PHASE2 | RECRUITING |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma |
PHASE1/PHASE2 | COMPLETED |
| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
PHASE2 | COMPLETED |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer |
PHASE2 | UNKNOWN |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer |
PHASE1 | RECRUITING |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
PHASE1 | SUSPENDED |
| A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
PHASE1 | RECRUITING |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
PHASE1 | RECRUITING |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors |
PHASE1 | SUSPENDED |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies |
PHASE1 | RECRUITING |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer |
PHASE1 | SUSPENDED |
| A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 |
PHASE1 | COMPLETED |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers |
PHASE1 | RECRUITING |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma |
PHASE1 | COMPLETED |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) |
PHASE1 | COMPLETED |
| Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma |
EARLY_PHASE1 | RECRUITING |
| Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor |
nan | NO_LONGER_AVAILABLE |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a BRD4 binder may also engage these)